Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.

Proceedings of the National Academy of Sciences of the United States of America - 25 May 2021

Cheng Derek K, Oni Tobiloba E, Thalappillil Jennifer S, Park Youngkyu, Ting Hsiu-Chi, Alagesan Brinda, Prasad Nadia V, Addison Kenneth, Rivera Keith D, Pappin Darryl J, Van Aelst Linda, Tuveson David A

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with limited treatment options. Although activating mutations of the KRAS GTPase are the predominant dependency present in >90% of PDAC patients, targeting KRAS mutants directly has been challenging in PDAC. Similarly, strategies targeting known KRAS downstream effectors have had limited clinical success due to feedback mechanisms, alternate pathways,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Neurofibromin 1

Share to Pancreas

Share to Proto-Oncogene Proteins p21(ras)

Share to Repressor Proteins

Share to Ribosomal Protein S6 Kinases, 90-kDa

Source

Open in PubMed Open full text

Identifiers

PMID: 34021083
DOI: 10.1073/pnas.2016904118
PMCID: PMC8166058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.PMID 34021083Read ↗

Oncogenic KRAS engages an RSK1/NF1 complex in pancreatic cancerSemantic proximity Read ↗

PI3K Regulates Wild-type RAS Signaling to Confer Resistance to KRAS Inhibition.Semantic proximity Read ↗

Phosphoinositide 3-kinase regulates wild-type RAS signaling to confer resistance to KRAS inhibitionSemantic proximity Read ↗

Oncogenic KRAS signalling in pancreatic cancerSemantic proximity Read ↗

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective TreatmentSemantic proximity Read ↗

Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer.Semantic proximity Read ↗

Pancreatic Cells Are Resistant to KRASQ61L Expression due to Hyperactive ERK/MAPK Signaling and Apoptosis Induction.Semantic proximity Read ↗

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity Read ↗

Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity.Semantic proximity Read ↗

AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer.Semantic proximity Read ↗

Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.